Biogen Makes Foray Into Opthalmology With AGTC Deal Biogen has struck a deal with AGTC to develop gene therapies that target eye diseases such as X-linked Retinoschisis and X-Linked Retinitis Pigmentosa. by Rhodi Lee
Xi Jinping Warns Against Chip Restrictions During Talks with Dutch PM Rutte: 'No Force Can Stop China's Progress'
Researchers Achieve Record Data Transmission Speed, 4.5 Million Times Faster Than Average Home Broadband